文献速递自身免疫性与大疱性皮肤病

大疱性类天疱疮系统与局部糖皮质激素治疗的死亡、主要不良心血管事件及复发风险比较

Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids.
PubMed 文献 · Br J Dermatol · 2024-01-01

基于TriNetX美国协作网络的回顾性队列研究,经倾向评分匹配年龄、性别、10种疾病和6种药物后比较大疱性类天疱疮患者使用系统性与局部糖皮质激素的风险。结果显示系统性激素组全因死亡风险(HR 1.43)、主要不良心血管事件(HR 1.33)和感染(HR 1.33)均升高,但疾病持续或复发风险降低(HR 0.85)。

要点

  • 系统性激素治疗与大疱性类天疱疮患者全因死亡风险升高相关(HR 1.43)。
  • 系统性激素组主要不良心血管事件和感染风险均升高(HR 1.33)。
  • 系统性激素组疾病持续或复发风险降低(HR 0.85)。

核心结论

  • 尽管系统性糖皮质激素治疗与大疱性类天疱疮复发风险降低相关,但其全因死亡风险显著高于局部糖皮质激素治疗。
  • 在缺乏前瞻性研究验证的情况下,局部糖皮质激素治疗可能因显著较低的死亡风险而优于系统性治疗。

研究设计与样本

  • 基于TriNetX美国协作网络的回顾性队列研究。
  • 采用倾向评分匹配年龄、性别、10种疾病和6种药物,并进行3项敏感性分析。
  • 系统性激素组n=2917,局部丙酸氯倍他索组n=2932。

主要发现

  • 系统性激素组全因死亡风险较局部丙酸氯倍他索组升高(HR 1.43,95%CI 1.28-1.58,P<0.001)。
  • 时间分层分析(1年和3年死亡率)及低剂量(泼尼松等效1-10 mg)或中高剂量(30-100 mg)系统性激素对比局部治疗的分析结果一致。
  • 系统性激素组主要不良心血管事件风险升高(HR 1.33,95%CI 1.08-1.64,P=0.008)。
  • 系统性激素组感染风险升高(HR 1.33,95%CI 1.15-1.54,P<0.001)。
  • 系统性激素组疾病持续或复发风险降低(HR 0.85,95%CI 0.77-0.94,P=0.002)。

关键数值与推荐

  • 全因死亡HR 1.43(95%CI 1.28-1.58,P<0.001),系统性激素组对比局部丙酸氯倍他索组。
  • 主要不良心血管事件HR 1.33(95%CI 1.08-1.64,P=0.008)。
  • 感染HR 1.33(95%CI 1.15-1.54,P<0.001)。
  • 疾病持续或复发HR 0.85(95%CI 0.77-0.94,P=0.002)。

临床怎么用

  • 在为大疱性类天疱疮患者选择糖皮质激素给药途径时,应权衡系统性治疗带来的死亡、心血管事件和感染风险升高与局部治疗可能增加的复发风险。
  • 局部糖皮质激素治疗可能因显著较低的死亡风险而成为更优选择,但需结合患者具体情况个体化决策。

局限性

  • 回顾性数据收集。
  • 治疗选择偏倚。
  • 编码错误可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: According to current guidelines, systemic or topical corticosteroids are both recommended as first-line treatments for bullous pemphigoid (BP). There is evidence to suggest that topical application may be associated with a lower risk of mortality. However, there is a lack of comprehensive large-scale data comparing mortality rates, as well as the risk of major adverse cardiac events (MACE), infections and relapse, between systemic and topical corticosteroid treatments. OBJECTIVES: To evaluate the risk of death, MACE, infections and relapse in patients with BP treated with systemic or topical corticosteroids. METHODS: A population-based retrospective cohort study was performed using the TriNetX US Collaborative Network. As a measure against bias, propensity score matching for age, sex, 10 diseases and 6 medications was done, and 3 sensitivity analyses were conducted. RESULTS: All-time risk of death was increased in US patients with BP exposed to any dose of systemic corticosteroids (n = 2917) vs. patients treated with topical clobetasol propionate [n = 2932; hazard ratio (HR) 1.43, 95% confidence interval (CI) 1.28-1.58 (P < 0.001)]. This was consistent in time-stratified analysis (1- and 3-year mortality rates) and in analysis contrasting prednisone (equivalent) doses of 1-10 mg (low) or 30-100 mg (medium-high) systemic corticosteroid to topical treatment. The increased risk of death in US patients with BP exposed to any dose of systemic corticosteroids vs. topical treatment was accompanied by increased risks for MACE (HR 1.33, 95% CI 1.08-1.64; P = 0.008) and infections (HR 1.33, 95% CI 1.15-1.54; P < 0.001). The risk of continued disease or relapse was decreased in patients treated with systemic vs. topical corticosteroids (HR 0.85, 95% CI 0.77-0.94; P = 0.002). Results regarding mortality and continued disease or relapse persisted in three sensitivity analyses. Potential limitations included the retrospective data collection, bias for treatment selection and miscoding. CONCLUSIONS: Pending validation in prospective studies, where feasible - and despite the heightened risk of relapse - topical corticosteroid treatment may be advantageous over systemic corticosteroid treatment owing to its significantly lower risk of death. Bullous pemphigoid (BP) is an autoimmune skin disease that commonly affects older people. The recommended treatment is medication called corticosteroids, either taken as a tablet or injection (‘systemic’) or applied to the skin (‘topical’). Some evidence suggests that topical corticosteroids might be safer in terms of the risk of dying. We looked at whether there was a difference between the risk of dying, having heart problems, getting sick or the condition coming back in people with BP who use the different medications. To do this, we used people’s past health information and compared people of similar ages and genders, 10 diseases and 6 medications. We found that people with BP who used systemic corticosteroids had a higher chance of dying. This also meant that people taking this form of the medication had a greater chance of having heart problems and getting infections. However, the risk of BP coming back was lower for people who used systemic corticosteroids. Our findings suggest that although there is a higher risk of BP coming back, there may be fewer risks from topical corticosteroids than systemic corticosteroids.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Bieber K, Vorobyev A, et al. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids. Br J Dermatol. 2024. PMID: 38798074. doi:10.1093/bjd/ljae219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。